阿加曲班在接受体外膜氧合支持患者中的应用:病例对照研究
该病例对照研究纳入北京朝阳医院呼吸重症监护病房(RICU)2013年7月1日至2022年2月28日接受ECMO的14例使用阿加曲班抗凝患者(其中2例初始即用阿加曲班,12例先用普通肝素后换用阿加曲班),并按人口学特征匹配28例使用普通肝素抗凝的患者。主要终点ECMO相关血栓事件发生率阿加曲班组28.6% vs 普通肝素组21.4%,ECMO相关出血事件28.6% vs 32.1%,ECMO期间死亡率35.7% vs 46.4%,差异均无统计学意义(均P<0.05)。阿加曲班组血小板输注量显著高于普通肝素组[U:7.7(0,10.0)vs 0.8(0,1.0)],血栓弹力图R值显著延长[分钟:9.3(7.2,10.8)vs 8.8(6.3,9.7)],MA值[mm:48.4(40.7,57.9)vs 52.6(45.4,61.5)]和α角[度:54.1(45.4,62.0)vs 57.9(50.2,69.0)]显著降低(均P<0.05)。阿加曲班初始剂量中位数0.049(0.029,0.103)μg×kg-1×min-1,维持剂量0.033(0.014,0.090)μg×kg-1×min-1,VV-ECMO患者维持剂量显著高于VA-ECMO和VAV-ECMO患者[μg×kg-1×min-1:0.102(0.059,0.127)vs 0.036(0.026,0.060)、0.013(0
要点
- 对存在普通肝素禁忌的ECMO患者,阿加曲班组ECMO相关血栓事件28.6% vs 普通肝素组21.4%,出血事件28.6% vs 32.1%,ECMO期间死亡率35.7% vs 46.4%,差异均无统计学意义(均P<0.05)。
- 阿加曲班维持剂量中位数0.033(0.014,0.090)μg×kg-1×min-1,VV-ECMO患者0.102(0.059,0.127)μg×kg-1×min-1,显著高于VA-ECMO的0.036(0.026,0.060)和VAV-ECMO的0.013(0.004,0.022)(均P<0.05)。
- 阿加曲班组血小板输注量显著高于普通肝素组[U:7.7(0,10.0)vs 0.8(0,1.0)],血栓弹力图R值显著延长[分钟:9.3(7.2,10.8)vs 8.8(6.3,9.7)],MA值和α角显著降低(均P<0.05)。
- 普通肝素换用阿加曲班后APTT延长[秒:63.5(58.4,70.6)vs 56.7(53.1,60.9)],血小板水平由普通肝素抗凝期间的下降趋势转为逐渐升高,D-二聚体换用后为19.1(7.0,28.7)mg/L且不再呈升高趋势。
- 作者认为阿加曲班似乎是普通肝素禁忌ECMO患者可行、有效且安全的替代抗凝剂。
适用人群与场景
- 2013年7月1日至2022年2月28日于北京朝阳医院呼吸重症监护病房(RICU)接受ECMO支持、存在普通肝素禁忌的危重症患者14例(阿加曲班组),其中2例初始即用阿加曲班,12例先用普通肝素后换用阿加曲班。
- 对照组为按人口学特征匹配的28例接受普通肝素抗凝的ECMO患者。
处置流程与药物剂量
- 阿加曲班初始剂量中位数0.049(0.029,0.103)μg×kg-1×min-1;VV-ECMO患者初始剂量最高[0.092(0.049,0.165)μg×kg-1×min-1],VAV-ECMO患者初始剂量最低[0.026(0.013,0.041)μg×kg-1×min-1],差异无统计学意义(P>0.05)。
- 阿加曲班维持剂量中位数0.033(0.014,0.090)μg×kg-1×min-1;VV-ECMO患者维持剂量0.102(0.059,0.127)μg×kg-1×min-1,显著高于VA-ECMO患者的0.036(0.026,0.060)μg×kg-1×min-1和VAV-ECMO患者的0.013(0.004,0.022)μg×kg-1×min-1(均P<0.05)。
研究设计与关键结果
- 研究类型为病例对照研究,阿加曲班组14例,普通肝素组28例;阿加曲班组VV-ECMO 8例、VA-ECMO 2例、VAV-ECMO 4例,普通肝素组VV-ECMO 23例、VA-ECMO 3例、VAV-ECMO 2例。
- 主要终点ECMO相关血栓事件发生率阿加曲班组28.6% vs 普通肝素组21.4%;ECMO相关出血事件发生率28.6% vs 32.1%;ECMO期间死亡率35.7% vs 46.4%;差异均无统计学意义(均P<0.05)。
- 阿加曲班组ECMO运行时间略长于普通肝素组[天:16(7,21)vs 13(8,17)]。
- 阿加曲班组血小板输注量显著高于普通肝素组[U:7.7(0,10.0)vs 0.8(0,1.0)];血栓弹力图R值显著延长[分钟:9.3(7.2,10.8)vs 8.8(6.3,9.7)];MA值[mm:48.4(40.7,57.9)vs 52.6(45.4,61.5)]和α角[度:54.1(45.4,62.0)vs 57.9(50.2,69.0)]显著降低(均P<0.05)。
- 阿加曲班组由普通肝素换用阿加曲班后APTT延长[秒:63.5(58.4,70.6)vs 56.7(53.1,60.9)];血小板水平在普通肝素抗凝期间呈下降趋势,换用阿加曲班后逐渐升高;换用阿加曲班后D-二聚体为19.1(7.0,28.7)mg/L,此后不再呈升高趋势;纤维蛋白原在普通肝素抗凝期间呈下降趋势(最低23.6 g/L),换用阿加曲班后在16.8~26.2 g/L之间波动。
证据类型、等级与局限
- 证据类型:病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,阿加曲班似乎是存在普通肝素禁忌、接受ECMO支持患者可行、有效且安全的替代抗凝剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the safety and efficacy of argatroban applied as alternative anticoagulant in critical illness patients underwent extracorporeal membrane oxygenation (ECMO) with contraindications of unfractionated heparin (UFH), and to further explore the effective dose of argatroban.
METHODS: From July 1, 2013 to February 28, 2022, there were 14 patients who admitted in the respiratory intensive care unit (RICU) of Beijing Chao-Yang Hospital received ECMO and used argatroban for anticoagulation (argatroban group). Two of them received argatroban as the initial anticoagulant. The remaining 12 patients used UFH at first, and then switched to argatroban. UFH group included 28 patients who received UFH for anticoagulation after matching the demographic characteristics. Primary endpoint was the prevalence of ECMO-related thrombotic events. Secondary endpoints included the type of thrombotic events, prevalence of ECMO-related major bleeding events, bleeding sites, ICU mortality, mortality during ECMO, liver and kidney function, thrombelastogram, blood transfusion, dosage of argatroban, the dynamic changes of coagulation variables 4 days before and 7 days after argatroban treatment.
RESULTS: In argatroban group, there were 8 patients received veno-venous ECMO (VV-ECMO), 2 patients with veno-arterial ECMO (VA-ECMO), and 4 patients with veno-arterio-venous ECMO (VAV-ECMO). In UFH group, VV-ECMO was applied in 23 patients, VA-ECMO and VAV ECMO was established in 3 patients and 2 patients, respectively. In endpoint events, the incidence of ECMO related thrombotic events in argatroban group was slightly higher than that in UFH group (28.6% vs. 21.4%). The ECMO running time in argatroban group was slightly longer than that in UFH group [days: 16 (7, 21) vs. 13 (8, 17)]. The incidence of ECMO-related bleeding events (28.6% vs. 32.1%) and mortality during ECMO (35.7% vs. 46.4%) in argatroban group were slightly lower than those in UFH group. However, the differences were not statistically significant (all P < 0.05). The platelet transfusion in argatroban group was significantly higher than that in UFH group [U: 7.7 (0, 10.0) vs. 0.8 (0, 1.0)]. The coagulation reaction time (R value) in thrombelastography in argatroban group was significantly longer than that in UFH group [minutes: 9.3 (7.2, 10.8) vs. 8.8 (6.3, 9.7)]. The maximum width value [MA value, mm: 48.4 (40.7, 57.9) vs. 52.6 (45.4, 61.5)] and blood clot generation rate [α-Angle (deg): 54.1 (45.4, 62.0) vs. 57.9 (50.2, 69.0)] in the argatroban group were significantly lower than those in the UFH group (all P < 0.05). The activated partial thromboplastin time (APTT) was prolonged after changing from UFH to argatroban in the argatroban group [seconds: 63.5 (58.4, 70.6) vs. 56.7 (53.1, 60.9)]. The PLT level showed a decreasing trend during UFH anticoagulation therapy, and gradually increased after changing to argatroban. D-dimer level was 19.1 (7.0, 28.7) mg/L after switching to argatroban, and then no longer showed an increasing trend. The level of fibrinogen (FIB) showed a decreasing trend during the anticoagulant therapy of UFH (the lowest was 23.6 g/L), and fluctuated between 16.8 and 26.2 g/L after changing to argatroban. The median initial dose of argatroban was 0.049 (0.029, 0.103) μg×kg-1×min-1, which the highest dose was in VV-ECMO patients of [0.092 (0.049, 0.165) μg×kg-1×min-1]. The initial dose of VAV-ECMO was the lowest [0.026 (0.013, 0.041) μg×kg-1×min-1], but without significant difference (P > 0.05). The maintenance dose of argatroban was 0.033 (0.014, 0.090) μg×kg-1×min-1, VV-ECMO patients was significantly higher than those in VA-ECMO and VAV-ECMO patients [μg×kg-1×min-1: 0.102 (0.059, 0.127) vs. 0.036 (0.026, 0.060), 0.013 (0.004, 0.022), both P < 0.05].
CONCLUSIONS: Argatroban appears to be a feasible, effective and safety alternative anticoagulant for patients with contraindications to UFH who undergoing ECMO support.
参考来源
- Zhang Z, Tang X, Wang R, et al. [Application of argatroban in patients receiving extracorporeal membrane oxygenation support: a case-control study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36567588. doi:10.3760/cma.j.cn121430-20220701-00621
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。